Mechanism

Trial

Studied treatment

Control

Patients

REVIVE II, 2013

Intravenous Levosimendan

placebo

patients with decompensated chronic heart failure

REVIVE-I, 2003

levosimendan 0.1–0.2 mg/kg/min

placebo

patienst with HF andsymptoms at rest

RUSSLAN, 2002

Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h

placebo

patients with left ventricular failure complicating acute myocardial infarction

calcium sensitiser